Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

64.71 -5.98 (-8.46%)
Streaming Delayed Price Updated: 1:04 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
From Tempus AI, Inc.
Via Business Wire
News headline image
AI Found an Influenza Target That Survives Viral Mutation
Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT) 
From Equity Insider
Via GlobeNewswire
News headline image
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports Second Quarter 2026 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
From Tempus AI, Inc
Via Business Wire
News headline image
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
From Tempus
Via Business Wire
News headline image
Tempus to Report Second Quarter 2026 Financial Results on July 30
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
From Tempus AI, Inc.
Via Business Wire
News headline image
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
From Ambry Genetics
Via Business Wire
News headline image
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
From Tempus AI, Inc.
Via Business Wire
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
From Ambry Genetics
Via Business Wire
News headline image
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports First Quarter 2026 Results
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.